Enhanced inhibitory effect from interaction of curcumin with amphotericin B or fluconazole against Candida species

Journal of Food and Drug Analysis

Volumn 8, Issue 3, 2000, Pages 208-212

  Tsao, Shyh Ming ^a   Yin, Mei Chin ^b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b Institute of Nutritional Science Chungshan Medical and Dental College   (Taiwan)

Author keywords

Amphotericin B; Candida species; Curcumin; Fluconazole

Indexed keywords

AMPHOTERICIN B; CURCUMIN; FLUCONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDIASIS; DRUG MIXTURE; DRUG POTENTIATION; FUNGEMIA; FUNGUS GROWTH; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

CANDIDA; FUNGI;

EID: 0033694949     PISSN: 10219498     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Beck, S. and Jarvis, W. R. 1993. The national nosocomial infections surveillance system: secular trends in the epidemiology of nosocomial infections in the United States, 1980-1990. J. Infect. Dis. 167: 147-151.
2. Meunier, F. 1989. Candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 8: 438-477.
3. Saral, R. 1991. Candida and Aspergillus infections in immunocompromised patients: An overview. Rev Infect. Dis. 13: 487-492.
4. Ang, B. S. P., Telenti, A. and King, B. 1993. Candidemia from a urinary tract source; microbiological aspects and clinical significance. Clin. Infect. Dis. 7: 662-666.
5. Chabot, G. G., Pazdur, R., Valeriote, F. A. and Baker, L.H. 1989. Pharmacokinetics and toxicity of continuous infusion of amphotericin B in cancer patients. J. Pharm. Sci. 78: 307-310.
6. Hartsel, S. and Bolard, J. 1996. Amphotericin B: new life for an old drug. Trends Pharm. Sci. 17: 445-449.
7. Rex, J. H., Benett, J. E. and Sugar, A. M. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. New England J. Med. 331: 1325-1330.
8. Bodey, G. P., Anaissie, E. J. and Elting, L. S. 1994. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 73: 2099-2106.
9. Rex, J. H., Rinaldi, M. G. and Pfaller, M. A. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39: 1-8.
10. Masuda, T., Jitoe, A., Isobe, J. and Nakatani, N. 1993. Antioxidative and antiinflammatory curcumin-related phenolics from rhizomes of Curcuma domestica. Phytochemistry 32: 1557-1560.
11. Govindarajan, V. S. 1980. Turmeric-chemistry, technology and quality. CRC Crit. Rev. Food Sci. Nutr. 12: 199-301.
12. Mukhopadyay, A., Basu, N., Ghatak, N. and Gujral, P.K. 1982. Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents Actions 12: 508-512.
13. Conney, A. H., Lysz, T., Ferraro, T. and Abidi, T. F. 1991. Inhibitory effect of curcumin and some related dietary compounds on tumour promotion and arachidonic acid metabolism in mouse skin. Avd. Enzyme. Regul. 31: 385-396.
14. Kelloff, G. J., Boone, C. W., Crowell, J. A., Steele, V. E., Luber, R. and Sigman, C. C. 1994. Chemopreventive drug development: Perspective and progress. Cancer Epidemiol. Biomarkers. Prev. 3: 85-98.
15. Li, C. J., Zhang, L. J., Dezube, B. J., Crumpacker, C. S. and Pardee, A. B. 1993. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc. Natl. Acad. Sci. USA 90: 1839-1842.
16. Warren, N. G. and Hazen, K. C. 1995. Candida, Cryptococcus and other yeasts of medical importance. In "Manual of Clinical Microbiology". 6th ed. pp. 723-737. American Society for Microbiology, Washington, D.C. U.S.A.
17. National Committee for Clinical Laboratory Standards. 1997. Reference methods for broth dilution antifungal susceptibility testing of yeasts. Standards M27-A. National Committee for Clinical Laboratory Standards, Wayne, PA. U.S.A.
18. Marco, F., Pfaller, M. A., Messer, S. and Jones, R.N. 1998. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 42: 161-163.
19. Bourne, K. Z., Bourne, N., Reising, S. F. and Stanberry, L. R. 1999. Plant products as topical microbicide candidates: assessment of in vitro and in vivo activity against herpes simplex virus type 2. Antiviral Res. 42: 219-226.
20. Van den Bossche, H., Marichal, P., Gorrens, J., Coene, M. C., Willemsens, G., Bellens, D., Roels, I., Moereels, H. and Janssen, P. A. J. 1989. Biochemical approaches to selective antifungal activity. Focus on azole antifungals. Mycoses 32: 35-52.
21. Joly, V., Bolard, J. and Yeni, P. 1992. In vitro models for studying toxicity of antifungal agents. Antimicrob. Agents Chemother. 39: 1799-1804.
22. Huang, M. T., Smart, R. C., Wong, C. Q. and Conney, A. H. 1988. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid and ferulic acid on tumor promotion in mouse skin by 12-O-teradecanoyphorbol-13-acetate. Cancer Res. 48: 5941-5946.
23. Hoult, J. R. S., Moroney, M. A. and Paya, M. 1994. Action of flavonoids and coumarins on lipoxygenases and cyclooxygenase. Methods Enzymol. 234: 443-455.
24. Ammon, H. P. and Wahl, M. A. 1991. Pharmacology of Curcuma longa. Planta Med. 57: 1-7.
25. Pan, M. H., Huang, T. M. and Lin, J.K. 1999. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metabolism Disposition 27:486-494.
26. Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R. and Srinivas, P. 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 64: 353-356.